Racial disparities in molecular subtypes of endometrial cancer

Gynecologic Oncology

Volumn 149, Issue 1, 2018, Pages 106-116

  Dubil, Elizabeth A ^a,b   Tian, Chunqiao ^a   Wang, Guisong ^a   Tarney, Christopher M ^a,c   Bateman, Nicholas W ^a,c   Levine, Douglas A ^d   Conrads, Thomas P ^a,c,e   Hamilton, Chad A ^a,c   Maxwell, George Larry ^a,c,e,f   Darcy, Kathleen M ^a,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e Inova Schar Cancer Institute   (United States)

^f INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Endometrial cancer; Mitotic subtype; Molecular subtypes; Racial disparities

Indexed keywords

LIVIN; POLO LIKE KINASE 1;

ADULT; AGED; ARTICLE; BLACK PERSON; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CELL PROLIFERATION; CLINICAL FEATURE; COPY NUMBER VARIATION; DIAGNOSTIC VALUE; ENDOMETRIUM CANCER; ENDOMETRIUM CANCER MOLECULAR SUBTYPE; HUMAN; MAJOR CLINICAL STUDY; MITOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; RNA SEQUENCE; UPREGULATION; CANCER GRADING; ENDOMETRIUM TUMOR; ETHNOLOGY; FEMALE; GENETICS; HEALTH DISPARITY; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS;

EID: 85044382332     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.12.009     Document Type: Article

References (40)

1. Siegel, R.L.M.K., Jemal, A., Cancer statistics, 2017. CA Cancer J. Clin. 67 (2017), 7–30.
2. Madison, T.S.D., James, S.A., Schwartz, A.G., Gruber, S.B., Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am. J. Public Health 94 (2004), 2104–2111.
3. Smotkin, D.N.N., Harris, K., Einstein, M.H., Yu, Y., Goldberg, G.L., Histopathologic differences account for racial disparity in uterine cancer survival. Gynecol. Oncol. 127 (2012), 616–619.
4. NA, Howlader N., Krapcho, M., Miller, D., Bishop, K., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J., Cronin, K.A., (eds.) SEER Cancer Statistics Review, 1975–2014, 2017, National Cancer Institute, Bethesda, MD https://seer.cancer.gov/csr/1975_2014/ based on November 2016 SEER data submission.
5. Cook, L.S.N.H., Cockburn, M., Olson, S.H., Muller, C.Y., Wiggins, C.L., Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites. Cancer Causes Control 24 (2013), 61–69.
6. Ruterbusch, J.J.A.-F.R., Olson, S.H., Sealy-Jefferson, S., Rybicki, B.A., Hensley-Alford, S., Elshaikh, M.A., Gaba, A.R., Schultz, D., Munkarah, A.R., Cote, M.L., The influence of comorbid conditions on racial disparities in endometrial cancer survival. Am. J. Obstet. Gynecol., 211, 2014, 627.e621-629.
7. Kost, E.R.H.K., Hines, J.F., Farley, J.H., Nycum, L.R., Rose, G.S., Carlson, J.W., Fischer, J.R. Jr., Kendall, B.S., Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancer. Gynecol. Oncol. 89 (2003), 218–226.
8. Maxwell, G.L.T.C., Risinger, J., Brown, C.L., Rose, G.S., Thigpen, J.T., Fleming, G.F., Gallion, H.H., Brewster, W.R., Gynecologic Oncology Group study. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer 107 (2006), 2197–2205.
9. Long, B.L.F., Bristow, R.E., Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. Gynecol. Oncol. 130 (2013), 652–659.
10. Bregar, A.J.A.R.-H.J., Spencer, R., Clemmer, J.T., Schorge, J.O., Rice, L.W., Del Carmen, M.G., Disparities in receipt of care for high-grade endometrial cancer: a National Cancer Data Base analysis. Gynecol. Oncol. 145 (2017), 114–121.
11. Gaber, C.M.R., Ruterbusch, J.J., Cote, M.L., Endometrial cancer trends by race and histology in the USA: projecting the number of new cases from 2015 to 2040. J. Racial Ethn. Health Disparities 4 (2017), 895–903.
12. The Cancer Genome Atlas Research Network, KC, Schultz N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., Yau, C., Laird, P.W., Ding, L., Zhang, W., Mills, G.B., Kucherlapati, R., Mardis, E.R., Levine, D.A., Integrated genomic characterization of endometrial carcinoma. Nature 497 (2013), 67–73.
13. Institute B, TCGA Genome Data Analysis Center (2016): Analysis-ready standardized TCGA data from Broad GDAC Firehose stddata__2015_11_01 run. 2016, Broad Institute of MIT and Harvard. Dataset.
14. Robinson, M.D.M.D., Smyth, G.K., edgeR (2009): a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26 (2009), 139–140.
15. WL, Yu G., Han, Y., He, Q., clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16 (2012), 284–287.
16. HQ, Yu G., ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol. BioSyst. 12 (2016), 477–479.
17. Luo, W.P.G., Bhavnasi, Y.K., Blanchard, S.G. Jr., Brouwer, C., Pathview Web: user friendly pathway visualization and data integration. Nucleic Acids Res. 45 (2017), W501–508.
18. Gayar, O.H.R.J., Parikh, K., Lu, M., Buekers, T., Munkarah, A., Elshaikh, M.A., Hysterectomy for uterine adenocarcinoma in the elderly: tumor characteristics, and long-term outcome. Gynecol. Oncol. 123 (2011), 71–75.
19. Oliver, K.E.E.L., Zhu, K., Conrads, T.P., Rose, G.S., Maxwell, G.L., Farley, J.H., Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment. Gynecol. Oncol. 123 (2011), 76–81.
20. Al Feghali, K.A.R.J., Mahan, M., Burmeister, C., Khan, N.T., Rasool, N., Munkarah, A., Elshaikh, M.A., Predictive capacity of 3 comorbidity indices in estimating survival endpoints in women with early-stage endometrial carcinoma. Int. J. Gynecol. Cancer 26 (2016), 1455–1460.
21. Tarney, C.M.T.C., Wang, G., Dubil, E.A., Bateman, N.W., Chan, J.K., Elshaikh, M.A., Cote, M.L., Schildkraut, J.M., Shriver, C.D., Conrads, T.P., Hamilton, C.A., Maxwell, G.L., Darcy, K.M., Impact of age at diagnosis on racial disparities in endometrial cancer patients. Gynecol. Oncol., 2017, 10.1016/j.ygyno.2017.07.145.
22. Farley, J.R.J., Rose, G.S., Maxwell, G.L., Racial disparities in blacks with gynecologic cancers. Cancer 110 (2007), 234–243.
23. Elshaikh, M.A.V.S., Kamal, M., Burmeister, C., Hanna, R.K., Rasool, N., Siddiqui, F., Influence of comorbidity on the risk of death: a single institution study of 1132 women with early-stage uterine cancer. Am. J. Clin. Oncol. 40 (2017), 183–188.
24. Allard, J.E.M.G., Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 16 (2009), 53–56.
25. Allard, J.E.C.G., Stagliano, K., Hood, B.L., Litzi, T., Shoji, Y., Boyd, J., Berchuck, A., Conrads, T.P., Maxwell, G.L., Risinger, J.I., Analysis of PSPHL as a candidate gene influencing the racial disparity in endometrial cancer. Front. Oncol., 2, 2012, 65.
26. Bateman, N.W.D.E., Wang, G., Hood, B.L., Oliver, J.M., Litzi, T.A., Gist, G.D., Mitchell, D.A., Blanton, B., Phippen, N.T., Tian, C., Zahn, C.M., Cohn, D.E., Havrilesky, L.J., Berchuck, A., Shriver, C.D., Darcy, K.M., Hamilton, C.A., Conrads, T.P., Maxwell, G.L., Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. Cancer 123:20 (2017), 4004–4012.
27. Maxwell, G.L.R.J., Hayes, K.A., Alvarez, A.A., Dodge, R.K., Barrett, J.C., Berchuck, A., Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin. Cancer Res. 6 (2000), 2999–3005.
28. Cote, M.L.A.G., Ruterbusch, J.J., Olson, S.H., Sealy-Jefferson, S., Rybicki, B.A., Alford, S.H., Elshaikh, M.A., Gaba, A.R., Schultz, D., Haddad, R., Munkarah, A.R., Ali-Fehmi, R., Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers. Int. J. Gynecol. Cancer 22 (2012), 1367–1372.
29. Santin, A.D.B.S., Siegel, E.R., Palmieri, M., Thomas, M., Cannon, M.J., Kay, H.H., Roman, J.J., Burnett, A., Pecorelli, S., Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am. J. Obstet. Gynecol. 192 (2005), 813–818.
30. MJ, Morrison C1., Darcy, K.M., Dolce, J.M., Kandel, E., Erwin, D.O., Liu, S., Shepherd, L., Cohn, D., DS, McMeekin, Block, A.W., Nowak, N.J., Maxwell, L., A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome. Genes Chromosom. Cancer 49 (2010), 791–802.
31. Cote, M.L.R.J., Olson, S.H., Lu, K., Ali-Fehmi, R., The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol. Biomark. Prev. 24 (2015), 1407–1415.
32. Cheng, J.L.X., Wang, J., Zhang, H., Duan, P., Li, C., Interactome analysis of gene expression profiles of cervical cancer reveals dysregulated mitotic gene clusters. Am. J. Transl. Res. 9 (2017), 3048–3059.
33. MJ, Hu Z., Curtis, C., Huang, G., Gu, S., Heiser, L., Lenburg, M.E., Korkola, J.E., Bayani, N., Samarajiwa, S., Seoane, J.A., Dane M, A., Esch, A., Feiler, H.S., Wang, N.J., Hardwicke, M.A., Laquerre, S., Jackson, J., Wood K, W., Weber, B., Spellman, P.T., Aparicio, S., Wooster, R., Caldas, C., Gray, J.W., Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res., 18, 2016, 70.
34. Otto, T.S.P., Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17 (2017), 93–115.
35. Au-Yeung, G.L.F., Azar, W.J., Mitchell, C., Jarman, K.E., Lackovic, K., Aziz, D., Cullinane, C., Pearson, R.B., Mileshkin, L., Rischin, D., Karst, A.M., Drapkin, R., Etemadmoghadam, D., Bowtell, D.D., Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin. Cancer Res. 23 (2017), 1862–1874.
36. Weiß, L.E.T., Polo-like kinase 1 as target for cancer therapy. Exp. Hematol. Oncol., 1, 2012, 38.
37. Lee, K.S.B.T.J., Park, J.E., Bang, J.K., Lee, E., Recent advances and new strategies in targeting Plk1 for anticancer therapy. Trends Pharmacol. Sci. 36 (2015), 858–877.
38. Liu, X., Targeting polo-like kinases: a promising therapeutic approach for cancer treatment. Transl. Oncol. 8 (2015), 185–195.
39. Mobahat, M.N.A., Riabowol, K., Survivin as a preferential target for cancer therapy. Int. J. Mol. Sci. 15 (2014), 2494–2516.
40. Berinstein, N.L.K.M., Oza, A.M., Odunsi, K., Villella, J.A., Nemunaitis, J.J., Morse, M.A., Pejovic, T., Bentley, J., Buyse, M., Nigam, R., Weir, G.M., MacDonald, L.D., Quinton, T., Rajagopalan, R., Sharp, K., Penwell, A., Sammatur, L., Burzykowski, T., Stanford, M.M., Mansour, M., Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology., 4, 2015, e1026529.